TABLE 1.
Patient characteristics
| Characteristic | Non-obese (n = 653) |
Obese (n = 272) |
|---|---|---|
| Female, n (%) (n = 923) | 346 (53.1) | 149 (55.0) |
| Age, y, median (range) | 54 (18–82) | 52 (11–78) |
| Diabetes, n (%) (n = 905) | 35 (5.4) | 51 (18.8) |
| Heart disease, n (%) (n = 904) | 52 (8.0) | 25 (9.2) |
| Lung disease, n (%) (n = 905) | 20 (3.1) | 12 (4.4) |
| ECOG, n (%) (n = 909) | ||
| 0 | 299 (45.8) | 118 (43.4) |
| 1 | 244 (37.4) | 106 (39.0) |
| 2 | 79 (12.1) | 33 (12.1) |
| ≥3 | 21 (3.2) | 9 (3.3) |
| Type of primary tumor, n (%) | ||
| Low-grade appendiceal | 189 (69.2) | 84 (30.8) |
| High-grade appendiceal | 74 (77.9) | 21 (22.1) |
| Colorectal | 145 (22.2) | 60 (22.1) |
| Other | 181 (27.7) | 77 (28.3) |
| Resection type, n (%) (n = 912) | ||
| R0/1 | 294 (45.4) | 137 (50.6) |
| R2a | 197 (30.2) | 64 (23.5) |
| R2b | 96 (14.7) | 39 (14.3) |
| R2c | 57 (8.7) | 28 (10.3) |
| Chemotherapeutic agent | ||
| Mitomycin C | 520 (79.6) | 205 (75.4) |
| Carboplatin | 30 (4.6) | 8 (2.9) |
| Cisplatin | 37 (5.7) | 15 (5.5) |
| Oxaliplatin | 72 (11.0) | 44 (16.2) |
| No. of organs resected, median (range) | 3 (0–9) | 3 (0–8) |
ECOG Eastern Cooperative Oncology Group performance status